Literature DB >> 15177263

Phenomics, lipodystrophy, and the metabolic syndrome.

Robert A Hegele1.   

Abstract

The metabolic syndrome (MetS) is a common multiplex cluster of phenotypes strongly related to cardiovascular disease that includes central obesity with hypertension, dyslipidemia, and type 2 diabetes. The core molecular defect of the MetS is insulin resistance; indeed, the terms "MetS" and "insulin resistance syndrome" often are used interchangeably. The successful translation to clinical medicine of molecular genetic research on other rare monogenic metabolic disorders has stimulated the evaluation of such rare monogenic forms of insulin resistance as partial lipodystrophy resulting from mutations in either LMNA or PPARG genes. Careful phenotypic evaluation of carriers of monogenic insulin resistance using a range of diagnostic methods--an approach sometimes called "phenomics"--may help to find early presymptomatic biomarkers of cardiovascular disease, which, in turn, may uncover new pathways and targets for interventions for the common MetS, diabetes, and atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15177263     DOI: 10.1016/j.tcm.2004.02.001

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  13 in total

1.  Congenital and environmental factors associated with adipocyte dysregulation as defects of insulin resistance.

Authors:  Chao-Ping Wang; Fu-Mei Chung; Shyi-Jang Shin; Yau-Jiunn Lee
Journal:  Rev Diabet Stud       Date:  2007-08-10

Review 2.  Genetic determinants of cardiometabolic risk: a proposed model for phenotype association and interaction.

Authors:  Piers R Blackett; Dharambir K Sanghera
Journal:  J Clin Lipidol       Date:  2012-04-22       Impact factor: 4.766

3.  Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy.

Authors:  Robert A Hegele; Henian Cao; Dora M Liu; Gary A Costain; Valentine Charlton-Menys; N Wilson Rodger; Paul N Durrington
Journal:  Am J Hum Genet       Date:  2006-06-05       Impact factor: 11.025

Review 4.  Kinase mutations in human disease: interpreting genotype-phenotype relationships.

Authors:  Piya Lahiry; Ali Torkamani; Nicholas J Schork; Robert A Hegele
Journal:  Nat Rev Genet       Date:  2010-01       Impact factor: 53.242

5.  Unbuckling lipodystrophy from insulin resistance and hypertension.

Authors:  Robert A Hegele; Todd Leff
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

6.  A clinical link between peroxisome proliferator-activated receptor γ and the renin-angiotensin system.

Authors:  Curt D Sigmund
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-04       Impact factor: 8.311

Review 7.  Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Kamran Qureshi; Gary A Abrams
Journal:  World J Gastroenterol       Date:  2007-07-14       Impact factor: 5.742

8.  A 9-year-old male with a duplication of chromosome 3p25.3p26.2: clinical report and gene expression analysis.

Authors:  Douglas C Bittel; Nataliya Kibiryeva; Majed Dasouki; Joan H M Knoll; Merlin G Butler
Journal:  Am J Med Genet A       Date:  2006-03-15       Impact factor: 2.802

9.  A phenomics-based strategy identifies loci on APOC1, BRAP, and PLCG1 associated with metabolic syndrome phenotype domains.

Authors:  Christy L Avery; Qianchuan He; Kari E North; Jose L Ambite; Eric Boerwinkle; Myriam Fornage; Lucia A Hindorff; Charles Kooperberg; James B Meigs; James S Pankow; Sarah A Pendergrass; Bruce M Psaty; Marylyn D Ritchie; Jerome I Rotter; Kent D Taylor; Lynne R Wilkens; Gerardo Heiss; Dan Yu Lin
Journal:  PLoS Genet       Date:  2011-10-13       Impact factor: 5.917

10.  Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3).

Authors:  Gordon A Francis; Gang Li; Robin Casey; Jian Wang; Henian Cao; Todd Leff; Robert A Hegele
Journal:  BMC Med Genet       Date:  2006-01-14       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.